ood morning, everyone, and welcome to another working week. We hope the weekend respite was refreshing and invigorating because, once again, that all-too-familiar routine of meetings, deadlines, and the like has returned. This was inevitable, yes? With that said, the time has come to rely on cups of stimulation to endure — the choice today is French vanilla, for those tracking this behavior — and you are invited to join us. Remember, no prescription is required. And so, here are your tidbits. Have a successful day and do keep in touch …

AstraZeneca will face a “substantial setback” if its most ambitious foray into immunotherapy falls flat, chief executive Pascal Soriot tells The Financial Times. An eagerly awaited study will show whether a lung cancer drug is better than chemotherapy at stopping cancer from getting worse, but not whether patients live longer. Results are due within weeks, but overall survival data are not due until next year and Soriot appears to be playing down expectations.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine